TrialBMC infectious diseases2022

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.

Robert Orenstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.